Jefferies Group’s Kyntra Bio KYNB Stock Holding History

Jefferies Group’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$455K	Buy	+1,400	New	+$451K	﹤0.01%	1063
2021 Q3	–	Sell	-1,148	Closed	-$764K	–	1806
2021 Q2	$764K	Buy	+1,148	New	+$661K	﹤0.01%	1062

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Jefferies Group's KYNB Position: Q3 2021 in Review

Jefferies Group sold out of Kyntra Bio (KYNB) in Q3 2021, closing a stake of 671 shares — an estimated $446K sold.

Jefferies Group first reported a position in KYNB in Q3 2019 and held it in 4 quarters. The position peaked at $679K in Q1 2020. 164 funds tracked by Wall St. Rank hold KYNB as of Q3 2021.

Jefferies Group reported no remaining Kyntra Bio position as of Q3 2021 after selling out during the quarter.
Jefferies Group sold 671 Kyntra Bio shares in Q3 2021, an estimated $446K.
Jefferies Group first reported a position in Kyntra Bio in Q3 2019 and held it in 4 quarters.
Jefferies Group's Kyntra Bio position peaked at $679K in Q1 2020.
164 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2021.

Based on Jefferies Group's 13F filing for Q3 2021, filed 15 Nov 2021.